Genomictree gets approval for publication in international journal on technology to co-deliver two tumor suppressor factors
Predicted impact: Low
Journal publication approval for a drug-delivery technology is routine and small versus company size.
Genomictree지노믹트리
228760 · KOSDAQ · ₩228760 · 지노믹트리
₩9,900▼ ₩500 (4.81%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −50.87%
- Market cap
- ₩246B
- Enterprise value
- ₩167B
- P/E
- —
- P/B
- 2.0×
- Dividend yield
- 0.0%
- ROE
- −7.4%
- Net margin
- −306.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.3% from the high
₩8,790Today: ₩9,750 – ₩10,300₩33,300
Returns
- 1W+6.8%
- 1M−9.6%
- 3M−4.2%
- 6M−42.3%
- YTD−63.9%
- 1Y−50.9%
- Volume today
- 61,913
- 0.6× the 20-day average
- Traded today
- ₩613M
- Listed shares
- 24,859,202
- EPS (12 months)
- −₩363
- Earnings yield −3.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A positive research publication approval, with no financial details. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-12.6% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Genomictree stock overview
Genomictree (지노믹트리, KRX: 228760) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean cancer molecular diagnostics firm founded in 2000 that develops blood-free, body-fluid-based tests using DNA methylation biomarkers to detect cancer early. Its shares closed at ₩9,900 on Oct 29, 2026, down 4.81% on the day, giving it a market value of ₩246B.
Key facts
- Market cap
- ₩246B
- Sector
- Biotech & Pharma
- Latest price change
- −4.81%
- As of
- Oct 29, 2026
- Main business
- The company is a Korean cancer molecular diagnostics firm founded in 2000 that develops blood-free, body-fluid-based tests using DNA methylation biomarkers to detect cancer early.
Quick answers about Genomictree
- What does Genomictree do?
- The company is a Korean cancer molecular diagnostics firm founded in 2000 that develops blood-free, body-fluid-based tests using DNA methylation biomarkers to detect cancer early. Its main product, EarlyTect Colon Cancer (EarlyTect-C), analyzes a stool sample to screen for colorectal cancer as an alternative to colonoscopy and is sold in South Korea mainly to clinics and health checkup centers on a non-covered basis. S.
- What is the market cap of Genomictree?
- The market capitalisation of Genomictree was ₩246B at the close on Oct 29, 2026.
- Who are the largest shareholders of Genomictree?
- According to the latest official filings, the largest reported holders are Oh Tae-jeong (0.58%, as of May 22, 2026); National Pension Service (0.51%, as of Dec 31, 2022); State Street(R) SPDR(R) S&P(R) International Small Cap ETF (0.05%, as of Jun 30, 2026).
- When is the next earnings report from Genomictree?
- Korean companies rarely announce results dates in advance. Based on when Genomictree filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 14, 2026.
- Does the National Pension Service own Genomictree?
- Yes. The National Pension Service held 0.51% of Genomictree shares as of Dec 31, 2022.
Company profile
The company is a Korean cancer molecular diagnostics firm founded in 2000 that develops blood-free, body-fluid-based tests using DNA methylation biomarkers to detect cancer early. Its main product, EarlyTect Colon Cancer (EarlyTect-C), analyzes a stool sample to screen for colorectal cancer as an alternative to colonoscopy and is sold in South Korea mainly to clinics and health checkup centers on a non-covered basis. The company is also developing EarlyTect tests for bladder, prostate and lung cancer, and is pursuing overseas markets through a U.S. subsidiary and a technology transfer partnership in China.
Written by AI from the company's latest annual report.
- Korean name
- 지노믹트리
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 안성환
- Founded
- Oct 2000
- Listed
- Mar 2019
- Listed shares
- 24,859,202
- Fiscal year ends
- Month 12
- Website
- genomictree.com/ko/
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
Recent filings
See all- Investor relations (IR) eventOct 27, 2026
- Investor relations (IR) eventAug 20, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Investor relations (IR) eventJul 3, 2026
- Insider shareholding reportMay 22, 2026
Titles in Korean until English translations are added.
Also known as: Genomictree / 지노믹트리 / 228760 / KRX:228760
Source: KRX statistical information